StockData
Electromed, Inc. logo

Electromed, Inc. (ELMD) company profile

ELMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 21/3028% below fair value
$23.13+0.03 (+0.13%)

Close on Nov 17, 2026Market cap $193.51MP/E 17.8Yield –

About Electromed

Electromedical & Electrotherapeutic Apparatus, SIC 3845

Electromed, Inc. develops, manufactures, markets, and sells medical devices that provide airway clearance therapy. Its core product offering is the SmartVest Airway Clearance System, available in models such as SmartVest SQL and SmartVest Clearway, along with Single Patient Use garments and wraps. These devices use high-frequency chest wall oscillation to clear retained mucus from the lungs. Electromed primarily serves individuals suffering from compromised pulmonary function associated with conditions like bronchiectasis, cystic fibrosis, and neuromuscular diseases. Its customer base includes homecare patients as well as inpatient populations within hospital intensive care and post-surgical units.

The company markets its products primarily in the United States across home health care and acute care hospital channels, and it maintains authorization for device distribution in select international countries. Electromed conducts its corporate operations from its principal executive offices located in New Prague, Minnesota.

Summary of the business section of Electromed's latest annual report, written by StockData.

Company profile

Company

Legal name
Electromed, Inc.
Founded
1992
Headquarters
New Prague, MN
Address
500 Sixth Avenue Nw 56071
Phone
(952) 758-9299
Employees
197, Jun 30, 2026
Industry
Electromedical & Electrotherapeutic Apparatus
Incorporated in
Minnesota
Fiscal year ends
June 30
Auditor
RSM US LLP, Minneapolis, Minnesota

Stock & identifiers

Ticker
ELMD
Exchange
NYSE
IPO date
Aug 13, 2010
Shares outstanding
8M, Aug 19, 2026
Public float
$223.72M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1488917
CUSIP
285409108
ISIN
US2854091087
FIGI
BBG000QN5ZH9
Share class FIGI
BBG001T853R7
EIN
41-1732920

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James L. CunniffCEO and President, Director145,080
Bradley M. NagelChief Financial Officer22,762
Kathleen SkarvanDirector39,184
Andrew SummersDirector282,367
Stan K. EricksonDirector40,317
Gregory FluetDirector21,000
Andrea M. WalshDirector18,000
Kathleen A. TuneDirector15,000
Joseph L. GalatowitschDirector15,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$1.81M$4.27M$836.16K$395–
FY2025
PEO1
$1.49M$4.85M$756.67K$205–
FY2025
PEO2
$0$0$756.67K$205–
FY2024
PEO1
$3.00M$4.40M$552.90K$140–
FY2024
PEO2
$0$0$552.90K$140–
FY2023$0$0$394.34K$111–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
James L. Cunniff
President and Chief Executive Officer
$536.80K$407.15K$405.69K$448.86K$14.42K$1.81M+22%
Bradley M. Nagel
Chief Financial Officer
$335.50K$126.94K$127.84K$224.43K$21.46K$836.16K+11%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 13, 2010
Offer price
$4.00
Securities offered
1,700,000
Gross proceeds
$6.80M
Exchange
Nasdaq
First trading day
Aug 13, 2010
First-day close
$3.98-0.5%
Lock-up ends (est.)
Feb 9, 2011

“Our common stock has been approved for listing on the Nasdaq Capital Market under the symbol “ELMD.” Per Share Total Initial public offering price $ 4.00 $ 6,800,000 Underwriting discount (1) $ 0.30 $ 510,000 Proceeds, before expenses, to Electromed, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had 197 employees, 195 of which were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?